Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Layout of monitoring points. by Yuhong Luo (3820411)

Additional file 3 of Single-cell profiling reveals a reduced epithelial defense system, decreased immune responses and the immune regulatory roles of different fibroblast subpopula... by Lin Lin (46073)

“…P values were calculated via the two-sided Wilcoxon test. ns, not significant, **, P < 0.01 and ****, P < 0.0001. (G) Feature plot showing LDLR expression levels in C1Q+ macrophages between CAG and control samples.…”

Correlation matrix depicting significant (p ≤ 0.05) Spearman correlations between the relative abundance of root endophytic bacterial major phyla/class and the chemical characteris... by Rabiath F. R. Adigoun (14189090)

Subjects:

Data Sheet 1_Secretoneurin plasma levels are decreased after catheter ablation for atrial fibrillation—patients with AF produce lower SN levels than healthy individuals: the SAFE r... by Jiří Plášek (21805048)

“…Plasma SN levels were significantly lower after the catheter ablation as compared with SN levels before (34.0 ± 15.1 and 40.0 ± 17.3 pmol/L, p = 0.032). …”

The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin... by Chanel Avenant (409756)

“…The substantial and differential decrease in testosterone and SHBG levels does not explain our previous finding of no detected decrease in risky sexual behavior or sexual function for DMPA-IM or NET-EN users from D0 to 25W. …”

Diversity of each focal taxon in Florida and the Atlantic Coastal Plain throughout the study interval. by Brendan M. Anderson (11234356)

Subjects:

Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography by Mengjing Ji (17741338)

Subjects:

Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography by Mengjing Ji (17741338)

Subjects:

Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography by Mengjing Ji (17741338)

Subjects:

Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography by Mengjing Ji (17741338)

Subjects:

Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography by Mengjing Ji (17741338)

Subjects:

Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography by Mengjing Ji (17741338)

Subjects:

Imaging CDK4/6 Broaden Options of Breast Cancer Diagnostics with Positron Emission Tomography by Mengjing Ji (17741338)

Subjects: